Several large-scale cardiovascular outcome trials (including LEADER, SUSTAIN-6, and REWIND) have shown that certain GLP-1 receptor agonists liraglutide, semaglutide, and dulaglutide reduce the risk of major adverse cardiovascular events such as heart attack, stroke, and cardiovascular death in people with established cardiovascular disease or multiple cardiovascular risk factors
This ingredient is produced from the starch of the fungus, Aureobasidium pullulans
Cell Death Differ 20:15801592
(15) Low levels of glutathione are associated with a higher risk of certain illnesses and conditions, such as type 2 diabetes, cancer, Parkinson's disease and hepatitis
I have a gut issue also You'll also get the latest articles directly to your inbox